image: Dr. Fred Saad, a researcher at the CHUM Research Centre, a Université de Montréal professor and the holder of the Raymond Garneau Chair in Prostate Cancer Research. view more
Credit: CHUM
This is among the findings of a phase lll clinical trial published in The Lancet Oncology by an international research team led by Dr. Fred Saad, a researcher at the CHUM Research Centre, a Université de Montréal professor and the holder of the Raymond Garneau Chair in Prostate Cancer Research.
The result of a collaboration with 167 hospitals in 17 countries, this study, called ACIS, identified for the first time a combination of three types of drugs said to slow the progression of metastases by more than 7 months. This is a significant therapeutic breakthrough for this difficult-to-treat disease, which is still fatal today.
Giving more time
To get these results, the international team recruited 982 men between the end of 2014 and the middle of 2016 and divided them randomly into two groups (randomized, double-blind trial). 492 volunteers received apalutamide (an anti-androgen) combined with abiraterone (an androgen synthesis inhibitor) and prednisone (an anti-inflammatory drug); 490 others received only abiraterone and prednisone.
This well-tolerated therapeutic trio was administered to patients with metastatic castration-resistant prostate cancer. Prostate cancer is considered castration-resistant when the cancer progresses despite hormone therapy.
By following the progression of the cancer through radiology, the scientists were able to show that the men in the first group lived 24 months (median) without signs of disease progression, compared to 16.6 months for those in the second group.
Additional studies will be needed to accurately identify the sub-categories of patients who would most benefit from this new treatment for metastatic castration-resistant prostate cancer.
About the study
The article “Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomized, placebo-controlled, double-blind, multinational, phase 3 study” by Dr. Fred Saad and his colleagues was published on September 30, 2021, in The Lancet Oncology.
About the CRCHUM
The University of Montreal Hospital Research Centre (CRCHUM) is one of North America’s leading hospital research centres. It strives to improve adult health through a research continuum covering such disciplines as the fundamental sciences, clinical research and public health. Over 2,300 people work at the CRCHUM, including more than 500 researchers and more than 520 graduate students. chumontreal.qc.ca/crchum
About Université de Montréal
Deeply rooted in Montreal and dedicated to its international mission, Université de Montréal is one of the top universities in the French-speaking world. Founded in 1878, Université de Montréal today has 13 faculties and schools, and together with its two affiliated schools, HEC Montréal and Polytechnique Montréal, constitutes the largest centre of higher education and research in Québec and one of the major centres in North America. It brings together 2,400 professors and researchers and has more than 67,000 students. umontreal.ca
Journal
The Lancet Oncology
Method of Research
Randomized controlled/clinical trial
Subject of Research
People
Article Title
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Article Publication Date
30-Sep-2021